A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

BRAF(V600E)-mutant malignant melanomas depend on RAF/MEK/ERK (MAPK) signaling for tumor cell growth(1). RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma(2, 3); however, resistance to these agents remains a formidable challenge(2, 4). Global characterization of resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannessen, Cory M., Johnson, Laura A., Piccioni, Federica, Townes, Aisha, Frederick, Dennie T., Donahue, Melanie K., Narayan, Rajiv, Flaherty, Keith T., Wargo, Jennifer A., Root, David E., Garraway, Levi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832/
https://www.ncbi.nlm.nih.gov/pubmed/24185007
http://dx.doi.org/10.1038/nature12688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832/
https://www.ncbi.nlm.nih.gov/pubmed/24185007
http://dx.doi.org/10.1038/nature12688

Ejemplares similares